AbbVie presents seven oncology assets while AbbVie stock costs EUR 253.55

Published on 10/23/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie presents seven oncology assets at ESMO on October 23, 2026. AbbVie stock costs EUR 253.55, and Q2 revenue reached USD 16.99 billion.

Oncology data and earnings dates

AbbVie presented seven oncology assets at ESMO on October 18, 2026.
Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock traded at EUR 253.55 at 11:09 a.m. CEST at Lang & Schwarz on October 23, 2026.
Third-quarter results are scheduled for October 30, 2026.

Redaktionsfoto des NYSE-Handelssaals mit Händlern und grünen Pharma-Aktiencharts auf Monitoren — AbbVie Inc. US00287Y1091 NYSE Handelssaal Editorial Fotografie Händler Pharma Aktiencharts grüne Kurven auf Monitoren, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 253.55 at Lang & Schwarz on October 23, 2026 at 11:09 a.m. CEST, as the company presented new oncology data at the European Society for Medical Oncology Congress. A Fidelity report on October 18, 2026 said the program covered seven assets across several tumor types.

Oncology pipeline reaches ESMO

The ESMO program supplied a measurable pipeline update. AbbVie reported that ABBV-706 produced a 56 percent overall response rate in a heavily pretreated small-cell lung cancer group, rising to 82 percent in a second-line-only subset. The company also reported that 90 percent of patients in an ABBV-969 prostate-cancer study achieved at least a 50 percent reduction in circulating tumor DNA by cycle three, according to Fidelity.

These figures broaden the investment discussion beyond AbbVie's established immunology franchise. They also remain clinical-stage indicators rather than booked revenue, so the October 30 earnings release will provide the next commercial test.

Three dates show the changing picture

AbbVie's chronology has three measurable steps. On July 31, 2026, second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year, while adjusted earnings per share came in at USD 3.65, according to MarketBeat. On October 6, 2026, the company cut third-quarter adjusted earnings-per-share guidance to USD 3.73-3.77 after USD 216 million of acquired in-process research and development and milestone expenses, also reported by MarketBeat. On October 18, 2026, AbbVie announced the seven-asset ESMO presentation program.

What dates matter next?

The ESMO Congress runs from October 23 through October 27, 2026, with presentations scheduled across the oncology portfolio. AbbVie will announce third-quarter 2026 financial results on October 30, 2026, before the market opens, according to the company release on AbbVie.

Pipeline data meets an earnings test

For investors, the key comparison is between clinical progress and near-term execution. Revenue growth of 10.20 percent in the second quarter provided a strong operating base, while the USD 3.73-3.77 adjusted earnings-per-share guidance range sets a lower bar for the third quarter. The next report will show whether the pipeline narrative is accompanied by fresh commercial momentum.

Stock price and company profile

AbbVie Inc. was trading at EUR 253.55 at Lang & Schwarz on October 23, 2026 at 11:09 a.m. CEST. The primary listing is on the NYSE, where the stock is quoted in USD; the structured market quote showed a market capitalization of USD 503.4 billion as of October 22, 2026 and a 52-week range of USD 190.75 to USD 291.40. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.